



## Transgene Announces Presentations at Upcoming Investor Conferences

---

**Strasbourg, France, May 12, 2014** – Transgene today announced that management will present at several investor conferences in May and June 2014 as outlined below.

**Forum Santé Gilbert Dupont:** Stéphane Boissel, Executive Vice President and Chief Financial Officer, will be meeting with institutional investors in Paris, France on May 13.

**Munich Capital Markets Conference:** Stéphane Boissel will give a corporate presentation on Tuesday, May 20 at 2:50 PM CET. The conference is being held in Munich, Germany.

**BioEquity Europe:** Stéphane Boissel will give a corporate presentation on Wednesday, May 21 at 4:40 PM CET and will participate in a panel discussion: “Fireside Chats: War Stories from Those Who Adapted” on Thursday, May 22 at 9:30 AM CET. The conference is being held in Amsterdam, The Netherlands.

**Jefferies Global Healthcare Conference:** Philippe Archinard, Chairman and Chief Executive Officer, will give a corporate presentation on Wednesday, June 4 at 10:30 AM EDT/4:30 PM CET. The presentation will be webcast, and a link to the live event as well as a replay, will be provided on Transgene’s website at [www.transgene.fr](http://www.transgene.fr). The conference is being held in New York, NY, USA.

### **About Transgene**

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of oncology and infectious diseases. Transgene’s programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology; this includes clinical-stage TG4001 for oropharyngeal cancer and TG1050 for hepatitis B in advanced pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at [www.transgene.fr](http://www.transgene.fr).

### **Contacts:**

#### **Transgene**

Elisabetta Castelli, Director IR  
+33 (0)3 88 27 91 21

Laurie Doyle, Director IR US  
& Corporate Communications  
+1 (339) 832 0752

[investorrelations@transgene.fr](mailto:investorrelations@transgene.fr)

#### **MC Services**

Raimund Gabriel  
+49 89 210 228 30  
[raimund.gabriel@mc-services.eu](mailto:raimund.gabriel@mc-services.eu)

Shaun Brown  
+44 207 148 5998  
[shaun.brown@mc-services.eu](mailto:shaun.brown@mc-services.eu)